# A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

> **NCT03971916** · PHASE1 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Chinese Volunteers

## Interventions

- **DRUG:** HBM9161(HL161BKN)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03971916
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2019-11-06
- **Final completion:** 2019-11-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971916, "A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03971916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*